Focused On-demand Library for Beta-microseminoprotein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P08118

UPID:

MSMB_HUMAN

Alternative names:

Immunoglobulin-binding factor; PN44; Prostate secreted seminal plasma protein; Prostate secretory protein of 94 amino acids; Seminal plasma beta-inhibin

Alternative UPACC:

P08118; B1API6; P11999; Q13125; Q6IAY9; Q9UC59

Background:

Beta-microseminoprotein, also known as Prostate secretory protein of 94 amino acids, plays a pivotal role in the seminal plasma. Known by alternative names such as Immunoglobulin-binding factor and Seminal plasma beta-inhibin, this protein is integral to reproductive biology. Its presence in seminal fluid underscores its importance in prostate function and seminal fluid balance.

Therapeutic significance:

Given its association with hereditary prostate cancer, understanding the role of Beta-microseminoprotein could open doors to potential therapeutic strategies. Its involvement in prostate cancer, particularly hereditary prostate cancer 13, highlights its potential as a biomarker for early detection and as a target for novel treatment approaches.